Contract Extension with Johnson & Johnson

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

Contract Extension with Johnson & Johnson Health Care Systems

Extension granted due to key engagement and satisfaction metrics achieved

Pharmaceutical verticals continue to scale

LONDON, U.K. AND NEW YORK, U.S. (18 February 2026). Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, announces a six-month contract extension with Johnson & Johnson Health Care Systems ("J&J") to continue to provide Trellus Elevate™, supporting patients with moderate to severely active inflammatory bowel disease ("IBD") who are prescribed a J&J therapy for treatment of IBD.

The collaboration with J&J, initially signed in January 2025, has been extended to mid-2026 with the same economic terms, including a fixed monthly management fee. A key factor in the extension was the achievement of engagement and satisfaction metrics during the initial pilot phase. Based on these metrics, J&J broadened the way patients can access the enrolment channels beyond the initial pilot funnel in mid-January 2026, reflecting continued confidence in the programme's performance.

This extension provides eligible patients prescribed a J&J therapy access to Trellus Elevate™, offering patients the tools and confidence to navigate the emotional and physical challenges of their conditions, staying engaged and adhering to their treatment plans.

The Company also continues to move forward with its TrialSet™ vertical, which is being deployed into agreed-upon sites with ICON plc for an ongoing, mid-stage immunology and inflammation clinical trial sponsored by Takeda. Trellus is also implementing TrialSet™ with PSI Inc. across two late-stage immunology and inflammation clinical trials sponsored by Sanofi and will be deployed into agreed-upon sites beginning mid-Q2.

Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health plc said, "The extension of our collaboration with J&J represents further external validation of our platform and the engagement outcomes achieved during the pilot phase. Together with the rollout of TrialSet™ with leading CRO partners, Trellus Health operates across the full programme lifecycle, from clinical trials through commercial deployment, using our proprietary resilience methodology to support engagement and programme success. We are establishing a scalable go-to-market model for pharma, with continued focus on disciplined execution, recurring revenue growth and expansion across immunology and inflammation. We look forward to updating the market on further developments."

Funding and Outlook

As previously disclosed, the Company expects revenue for the year ended 2025 to be c. $545,000 and has further reduced its monthly cash burn to c.$400,000 by late 2025 from c.$440,000 in October 2025. This was moderately offset by recurring monthly management fees generated during the second half of the year.

As announced previously, the Company has secured a £5 million convertible facility with Alumni Capital LLC, which was approved by shareholders on 20 January 2026. The net proceeds of the First Tranche Notes and Second Tranche Notes, (£737,500 in gross principal), are expected to extend the Company's cash runway into late Q1 2026. The Directors continue ongoing discussions regarding additional sources of funding to further extend the Company's cash runway, irrespective of the utilisation of the Notes.

The Board remains focused on accelerating commercial momentum by expanding the Company's footprint through strategic partnerships, deepening pharmaceutical partnerships and scaling TrialSet™ across additional programmes and sponsors. The Directors believe the recent contract extension, combined with ongoing CRO implementations, positions the Company to build increasing recurring revenue visibility through 2026.

Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Company's announcement released on 30 December 2025.

Enquiries:

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement

The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation. Both the founders continue to have a financial interest in the Company.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com